Immunocore Holdings Plc is a biotechnology company that specializes in the development of innovative T cell receptor-based therapies to treat a range of diseases, including cancer and autoimmune conditions

The company focuses on harnessing the power of the immune system by creating treatments designed to engage T cells, which play a critical role in the body's defense against diseases. Through its proprietary technology platform, Immunocore aims to develop a new class of drugs that can effectively target and destroy diseased cells while minimizing impact on healthy tissues. The company's research and clinical efforts are driven by a commitment to advancing science and improving patient outcomes in areas of significant unmet medical need.